In This Article:
The Indian market has shown robust performance, rising 1.2% over the last week and climbing 41% in the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| Goldiam International | 0.74% | 10.81% | 15.85% | ★★★★★★ |
| Vidhi Specialty Food Ingredients | 7.27% | 11.00% | 4.02% | ★★★★★★ |
| Yuken India | 27.96% | 12.35% | -44.41% | ★★★★★★ |
| ELANTAS Beck India | NA | 14.89% | 24.83% | ★★★★★★ |
| Timex Group India | 14.33% | 17.75% | 59.68% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 42.61% | 42.95% | ★★★★★★ |
| Gallantt Ispat | 18.85% | 37.56% | 37.26% | ★★★★★☆ |
| Master Trust | 37.05% | 27.64% | 41.99% | ★★★★★☆ |
| Genesys International | 12.13% | 15.75% | 36.33% | ★★★★★☆ |
Let's uncover some gems from our specialized screener.
Akums Drugs and Pharmaceuticals
Simply Wall St Value Rating: ★★★★★☆
Overview: Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients in India and internationally, with a market cap of ₹132.37 billion.
Operations: Akums generates revenue primarily from Contract Development and Manufacturing Organization (CDMO) services (₹36.32 billion), branded and generic formulations (₹6.76 billion), and active pharmaceutical ingredients (API) sales (₹3.03 billion). The company's net profit margin is a critical metric to evaluate its profitability.
Akums Drugs and Pharmaceuticals, a small-cap player in the pharmaceutical sector, has shown significant progress recently. The company reported sales of ₹10.19 billion for Q1 2024, up from ₹9.70 billion a year ago, with net income reaching ₹601.71 million compared to a net loss of ₹1.88 billion previously. Its net debt to equity ratio stands at 40%, which is satisfactory, and interest payments are well covered by EBIT (9.7x). The recent appointment of Mr. Shantanu R Chobhe as Corporate Quality Assurance Head underscores Akums' commitment to quality excellence and regulatory compliance.
Indegene
Simply Wall St Value Rating: ★★★★★☆
Overview: Indegene Limited operates as a life sciences commercialization company in India, the United States, Europe, and internationally with a market cap of ₹153.68 billion.